Healthcare Jan 10, 2022 09:37 AM (GMT+8) · EqualOcean
On the 10th, yiouda health learned that bluepha, the leader of domestic synthetic biology track, announced the completion of B3 round of financing. So far, the total financing of Series B has reached 1.5 billion yuan. The B3 round of financing of Lanjing microorganism is jointly led by Genesis capital and China's state-owned enterprise mixed ownership reform fund (mixed ownership reform fund). Zhongping capital, Jiangsu Huanghai financial holding group, Zhongzhou blue ocean follow-up investment, and the existing shareholders Fengrui capital, country garden venture capital, Gaoling venture capital and sany innovation investment continue to make additional investment, Taihe capital continues to serve as the exclusive financial advisor. Series B financing funds will be used for the construction and operation of large-scale production facilities for biodegradable materials PHA and synbio, an industrial 4.0 synthetic biology R & D platform_ The development and deployment of OS, and the R & D and landing of new product pipelines such as regenerative medical materials and engineering probiotics.

This text is a result of machine translation.